pamidronic acid ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 2048 40391-99-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pamidronic acid
  • pamidronate disodium
  • pamidronate
  • pamidronate disodium hydrate
An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies.
  • Molecular weight: 235.07
  • Formula: C3H11NO7P2
  • CLOGP: -4.32
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 6
  • TPSA: 161.31
  • ALOGS: -1.17
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.47 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 32 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 1991 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 753.34 18.26 273 11634 34850 63442265
Osteonecrosis 704.12 18.26 237 11670 24293 63452822
Bone disorder 239.27 18.26 104 11803 21222 63455893
Tooth extraction 216.62 18.26 79 11828 10185 63466930
Plasma cell myeloma 168.83 18.26 97 11810 35808 63441307
Atypical femur fracture 166.12 18.26 55 11852 5317 63471798
Sequestrectomy 160.35 18.26 36 11871 790 63476325
Bone debridement 145.23 18.26 27 11880 218 63476897
Malignant neoplasm progression 118.11 18.26 108 11799 82013 63395102
Infusion site coldness 116.60 18.26 22 11885 194 63476921
Debridement 111.73 18.26 29 11878 1189 63475926
Gamma-glutamyltransferase decreased 107.97 18.26 22 11885 298 63476817
Metastases to bone 104.72 18.26 59 11848 20960 63456155
Exposed bone in jaw 98.71 18.26 32 11875 2893 63474222
Bone sequestrum 97.01 18.26 27 11880 1447 63475668
Actinomycosis 96.32 18.26 25 11882 1025 63476090
Pain in jaw 90.95 18.26 71 11836 43425 63433690
Femur fracture 86.96 18.26 68 11839 41688 63435427
Hypocalcaemia 82.45 18.26 59 11848 31654 63445461
Osteomyelitis 80.79 18.26 54 11853 25966 63451149
Bone pain 78.78 18.26 72 11835 54569 63422546
Infusion site induration 78.66 18.26 22 11885 1200 63475915
Impaired healing 74.62 18.26 94 11813 102448 63374667
Cardiac output decreased 74.16 18.26 20 11887 952 63476163
Post-traumatic neck syndrome 67.19 18.26 22 11885 2052 63475063
Vasodilatation 64.08 18.26 22 11885 2373 63474742
Toothache 62.39 18.26 41 11866 19158 63457957
Vein disorder 60.65 18.26 26 11881 5115 63472000
Bone lesion excision 54.60 18.26 9 11898 32 63477083
Jaw disorder 50.07 18.26 23 11884 5326 63471789
Jaw operation 48.79 18.26 14 11893 838 63476277
Infusion site haemorrhage 48.02 18.26 22 11885 5064 63472051
Retinal detachment 47.66 18.26 23 11884 5946 63471169
Mean cell haemoglobin decreased 47.63 18.26 22 11885 5157 63471958
Spinal pain 47.48 18.26 30 11877 13109 63464006
Osteitis 43.43 18.26 18 11889 3256 63473859
Urine odour abnormal 43.24 18.26 22 11885 6367 63470748
Abscess jaw 41.92 18.26 14 11893 1388 63475727
Stress fracture 41.41 18.26 23 11884 7940 63469175
Mineral metabolism disorder 40.85 18.26 6 11901 7 63477108
Wound treatment 40.37 18.26 9 11898 191 63476924
Osteotomy 38.81 18.26 9 11898 229 63476886
Hypercalcaemia 38.24 18.26 36 11871 28286 63448829
Osteosclerosis 37.27 18.26 17 11890 3871 63473244
Peripheral coldness 37.16 18.26 25 11882 12140 63464975
Pathological fracture 36.57 18.26 22 11885 8812 63468303
Incontinence 35.75 18.26 24 11883 11608 63465507
Fistula 35.73 18.26 23 11884 10370 63466745
Tibia fracture 35.73 18.26 18 11889 5102 63472013
Blood creatinine decreased 34.37 18.26 18 11889 5527 63471588
Wound closure 33.44 18.26 7 11900 109 63477006
Bone lesion 33.38 18.26 18 11889 5863 63471252
Poor venous access 32.77 18.26 25 11882 14760 63462355
Skin sensitisation 31.11 18.26 10 11897 879 63476236
Blood test abnormal 29.41 18.26 24 11883 15605 63461510
Bone formation decreased 29.33 18.26 6 11901 83 63477032
Neoplasm progression 29.05 18.26 35 11872 36393 63440722
Osteolysis 28.92 18.26 13 11894 2861 63474254
Pneumonia influenzal 28.29 18.26 11 11896 1686 63475429
Tooth abscess 28.20 18.26 23 11884 14946 63462169
Blood potassium increased 28.08 18.26 25 11882 18284 63458831
Tumour marker increased 27.77 18.26 15 11892 4900 63472215
Contraindicated product administered 27.58 18.26 4 11903 217644 63259471
Hyperbaric oxygen therapy 27.28 18.26 5 11902 37 63477078
Mucosal inflammation 26.42 18.26 38 11869 46890 63430225
Body temperature decreased 25.86 18.26 25 11882 20294 63456821
Tooth disorder 25.70 18.26 29 11878 28128 63448987
Breast cancer 25.53 18.26 38 11869 48345 63428770
Blood parathyroid hormone increased 25.15 18.26 12 11895 3026 63474089
Wound dehiscence 25.05 18.26 14 11893 4889 63472226
Bone fistula 24.59 18.26 5 11902 67 63477048
Toxicity to various agents 24.38 18.26 8 11899 247242 63229873
Feeling cold 24.22 18.26 26 11881 23862 63453253
Arthropathy 24.22 18.26 7 11900 234785 63242330
Tumour lysis syndrome 23.98 18.26 17 11890 8973 63468142
Muscle spasms 23.97 18.26 74 11833 156076 63321039
Callus formation delayed 23.89 18.26 4 11903 16 63477099
Gastritis 23.68 18.26 32 11875 37271 63439844
Therapeutic product effect decreased 23.46 18.26 4 11903 193183 63283932
Aspergilloma 22.97 18.26 6 11901 252 63476863
Condition aggravated 22.93 18.26 25 11882 402192 63074923
Joint swelling 22.69 18.26 17 11890 327649 63149466
Immunodeficiency 22.23 18.26 23 11884 20231 63456884
Oedema peripheral 22.19 18.26 82 11825 189429 63287686
Rheumatoid arthritis 22.06 18.26 10 11897 253809 63223306
Musculoskeletal stiffness 22.03 18.26 4 11903 184614 63292501
Infusion site thrombosis 21.24 18.26 5 11902 136 63476979
Neutrophil count decreased 21.20 18.26 38 11869 56368 63420747
Metastases to liver 20.98 18.26 24 11883 23615 63453500
Gingival swelling 20.91 18.26 12 11895 4406 63472709
Product dose omission issue 20.72 18.26 9 11898 234304 63242811
Lymphatic disorder 20.66 18.26 6 11901 375 63476740
Oral surgery 20.58 18.26 8 11899 1226 63475889
Tumour marker abnormal 20.56 18.26 6 11901 381 63476734
Disease progression 20.55 18.26 60 11847 122698 63354417
Neuropathy peripheral 20.43 18.26 57 11850 113610 63363505
Feeling hot 20.32 18.26 35 11872 50319 63426796
Maternal exposure during pregnancy 20.19 18.26 8 11899 220054 63257061
Femoral neck fracture 20.19 18.26 15 11892 8508 63468607
Water intoxication 19.98 18.26 6 11901 421 63476694
Drug interaction 19.95 18.26 9 11898 229122 63247993
Periodontal destruction 19.80 18.26 3 11904 5 63477110
Osteomyelitis chronic 19.68 18.26 6 11901 443 63476672
Focal segmental glomerulosclerosis 19.23 18.26 8 11899 1460 63475655
Discomfort 19.18 18.26 4 11903 167370 63309745
Hepatic enzyme increased 19.15 18.26 7 11900 202321 63274794
Computerised tomogram abnormal 19.09 18.26 9 11898 2208 63474907
Blood calcium increased 18.96 18.26 15 11892 9335 63467780
Purulence 18.69 18.26 8 11899 1566 63475549

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 430.41 19.58 145 6487 14745 34935554
Osteonecrosis of jaw 294.48 19.58 115 6517 17774 34932525
Tooth extraction 164.29 19.58 53 6579 4675 34945624
Bone disorder 157.74 19.58 55 6577 6160 34944139
Plasma cell myeloma 153.92 19.58 97 6535 41940 34908359
Bone debridement 104.83 19.58 20 6612 186 34950113
Pain in jaw 79.53 19.58 42 6590 12998 34937301
Sequestrectomy 78.19 19.58 16 6616 219 34950080
Exposed bone in jaw 77.08 19.58 23 6609 1563 34948736
Debridement 75.40 19.58 20 6612 883 34949416
Atypical femur fracture 72.59 19.58 16 6616 318 34949981
Actinomycosis 61.64 19.58 15 6617 466 34949833
Hypercalcaemia 59.79 19.58 37 6595 15431 34934868
Osteomyelitis 58.36 19.58 37 6595 16099 34934200
Nephrocalcinosis 57.20 19.58 15 6617 633 34949666
Hyperbaric oxygen therapy 56.45 19.58 9 6623 24 34950275
Tibia fracture 52.29 19.58 17 6615 1533 34948766
Neuropathy peripheral 50.23 19.58 70 6562 83193 34867106
Femur fracture 49.05 19.58 26 6606 8098 34942201
Acute generalised exanthematous pustulosis 47.57 19.58 24 6608 6752 34943547
Hypocalcaemia 42.69 19.58 36 6596 24253 34926046
Purulent discharge 42.10 19.58 17 6615 2846 34947453
Impaired healing 38.36 19.58 28 6604 15306 34934993
Jaw fracture 37.30 19.58 12 6620 1046 34949253
Hepatitis B 35.70 19.58 19 6613 5964 34944335
Bone lesion excision 35.50 19.58 5 6627 3 34950296
Bone sequestrum 35.18 19.58 10 6622 572 34949727
Stress fracture 30.42 19.58 10 6622 933 34949366
Foot fracture 30.14 19.58 16 6616 4995 34945304
Jaw operation 29.36 19.58 7 6625 199 34950100
Pancytopenia 26.70 19.58 57 6575 95100 34855199
Fistula 25.51 19.58 16 6616 6824 34943475
Pustular psoriasis 24.99 19.58 10 6622 1635 34948664
Wound closure 24.26 19.58 5 6627 71 34950228
Deep vein thrombosis 24.26 19.58 44 6588 65204 34885095
Carcinoid tumour 23.39 19.58 6 6626 232 34950067
Bone swelling 22.88 19.58 6 6626 253 34950046
Jaw disorder 22.30 19.58 10 6622 2165 34948134
Bone lesion 22.28 19.58 11 6621 2952 34947347
CSF white blood cell count decreased 21.97 19.58 4 6628 28 34950271
Drug interaction 21.53 19.58 8 6624 225938 34724361
Chronic fatigue syndrome 20.75 19.58 6 6626 365 34949934
Maxillofacial operation 20.63 19.58 3 6629 3 34950296
Pneumonia 19.91 19.58 127 6505 362500 34587799
Bone pain 19.87 19.58 22 6610 20664 34929635
Extraskeletal ossification 19.81 19.58 4 6628 51 34950248
CSF white blood cell count increased 19.60 19.58 4 6628 54 34950245

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 978.58 16.96 324 15023 30771 79698270
Osteonecrosis of jaw 970.94 16.96 350 14997 42876 79686165
Tooth extraction 395.65 16.96 127 15220 10868 79718173
Bone disorder 388.42 16.96 144 15203 18969 79710072
Plasma cell myeloma 274.22 16.96 154 15193 53105 79675936
Bone debridement 248.58 16.96 47 15300 408 79728633
Sequestrectomy 224.29 16.96 48 15299 814 79728227
Debridement 185.65 16.96 47 15300 1698 79727343
Actinomycosis 169.24 16.96 40 15307 1079 79727962
Atypical femur fracture 162.57 16.96 54 15293 5135 79723906
Pain in jaw 151.27 16.96 100 15247 46051 79682990
Osteomyelitis 142.37 16.96 85 15262 32780 79696261
Bone sequestrum 140.17 16.96 35 15312 1194 79727847
Exposed bone in jaw 129.79 16.96 42 15305 3678 79725363
Metastases to bone 121.19 16.96 69 15278 24358 79704683
Malignant neoplasm progression 118.02 16.96 138 15209 135852 79593189
Infusion site coldness 113.81 16.96 22 15325 217 79728824
Impaired healing 113.40 16.96 110 15237 87545 79641496
Femur fracture 108.22 16.96 76 15271 38576 79690465
Gamma-glutamyltransferase decreased 103.40 16.96 22 15325 362 79728679
Hypocalcaemia 99.32 16.96 80 15267 49844 79679197
Bone pain 93.64 16.96 81 15266 55661 79673380
Bone lesion excision 89.14 16.96 14 15333 32 79729009
Hyperbaric oxygen therapy 84.96 16.96 14 15333 48 79728993
Infusion site induration 79.71 16.96 22 15325 1113 79727928
Jaw operation 76.80 16.96 20 15327 809 79728232
Hypercalcaemia 73.09 16.96 60 15287 38370 79690671
Fistula 70.83 16.96 39 15308 12901 79716140
Stress fracture 69.88 16.96 31 15316 6449 79722592
Jaw disorder 67.33 16.96 28 15319 4978 79724063
Post-traumatic neck syndrome 66.42 16.96 22 15325 2072 79726969
Cardiac output decreased 61.07 16.96 20 15327 1818 79727223
Nephrocalcinosis 60.83 16.96 19 15328 1483 79727558
Vein disorder 59.80 16.96 26 15321 5156 79723885
Wound closure 58.90 16.96 12 15335 158 79728883
Osteotomy 58.61 16.96 13 15334 262 79728779
Wound treatment 57.38 16.96 12 15335 181 79728860
Vasodilatation 57.36 16.96 22 15325 3169 79725872
Toothache 55.26 16.96 39 15308 19931 79709110
Infusion site haemorrhage 54.09 16.96 22 15325 3698 79725343
Bone lesion 50.30 16.96 24 15323 5895 79723146
Pathological fracture 47.56 16.96 28 15319 10509 79718532
Drug interaction 47.25 16.96 11 15336 415172 79313869
Purulent discharge 43.87 16.96 22 15325 6017 79723024
Tibia fracture 43.32 16.96 21 15326 5340 79723701
Mean cell haemoglobin decreased 43.24 16.96 22 15325 6202 79722839
Urine odour abnormal 43.08 16.96 22 15325 6251 79722790
Jaw fracture 41.00 16.96 17 15330 3000 79726041
Toxicity to various agents 40.95 16.96 15 15332 421525 79307516
Spinal pain 40.14 16.96 29 15318 15363 79713678
Osteitis 39.76 16.96 18 15329 3925 79725116
Abscess jaw 38.55 16.96 14 15333 1733 79727308
Neuropathy peripheral 38.04 16.96 84 15263 141221 79587820
Retinal detachment 37.65 16.96 23 15324 9224 79719817
Osteolysis 37.50 16.96 18 15329 4480 79724561
Peripheral coldness 36.96 16.96 28 15319 15942 79713099
Osteosclerosis 36.51 16.96 17 15330 3954 79725087
Pneumonia influenzal 34.91 16.96 15 15332 2889 79726152
Maxillofacial operation 33.84 16.96 5 15342 6 79729035
Blood parathyroid hormone increased 32.46 16.96 15 15332 3430 79725611
Hepatitis B 32.09 16.96 20 15327 8312 79720729
Body temperature decreased 31.87 16.96 35 15312 32110 79696931
Metastases to skin 31.29 16.96 12 15335 1727 79727314
Adenocarcinoma of colon 31.15 16.96 17 15330 5524 79723517
Foot fracture 31.08 16.96 29 15318 21952 79707089
Incontinence 30.95 16.96 24 15323 14140 79714901
Tooth disorder 30.33 16.96 31 15316 26202 79702839
Skin sensitisation 29.75 16.96 10 15337 985 79728056
Poor venous access 29.70 16.96 26 15321 18123 79710918
Bone fistula 28.91 16.96 6 15341 87 79728954
Osteomyelitis chronic 28.90 16.96 9 15338 695 79728346
Acute generalised exanthematous pustulosis 28.80 16.96 25 15322 17229 79711812
Oral surgery 28.58 16.96 10 15337 1111 79727930
Dental operation 28.23 16.96 10 15337 1152 79727889
Blood creatinine decreased 28.17 16.96 18 15329 7807 79721234
Tooth abscess 28.10 16.96 24 15323 16186 79712855
Muscle spasms 26.61 16.96 84 15263 174646 79554395
Tumour marker increased 26.52 16.96 14 15333 4258 79724783
Blood test abnormal 26.27 16.96 24 15323 17686 79711355
Neoplasm progression 25.64 16.96 40 15307 51642 79677399
Gingival swelling 25.52 16.96 14 15333 4595 79724446
Product dose omission issue 25.42 16.96 8 15339 247529 79481512
Tumour lysis syndrome 25.37 16.96 27 15320 23912 79705129
Plastic surgery 24.39 16.96 5 15342 68 79728973
Metastases to lung 23.84 16.96 23 15324 18140 79710901
Periodontal destruction 23.79 16.96 4 15343 16 79729025
Callus formation delayed 23.79 16.96 4 15343 16 79729025
Wound dehiscence 23.32 16.96 15 15332 6580 79722461
Stem cell transplant 22.60 16.96 12 15335 3692 79725349
Blood potassium increased 22.55 16.96 28 15319 29247 79699794
Purulence 22.20 16.96 10 15337 2155 79726886
Arteriovenous fistula thrombosis 22.19 16.96 7 15340 564 79728477
Immunodeficiency 22.10 16.96 24 15323 21744 79707297
Tumour marker abnormal 22.04 16.96 6 15341 288 79728753
Metastases to liver 21.68 16.96 27 15320 28287 79700754
Oedema peripheral 21.62 16.96 101 15246 252187 79476854
Gingival erythema 21.33 16.96 7 15340 640 79728401
Lymphatic disorder 21.18 16.96 6 15341 334 79728707
Bone swelling 21.09 16.96 9 15338 1705 79727336
Oral cavity fistula 20.72 16.96 7 15340 700 79728341
Condition aggravated 20.47 16.96 41 15306 501083 79227958
Hepatic enzyme increased 20.42 16.96 5 15342 182605 79546436
Contraindicated product administered 20.40 16.96 3 15344 157535 79571506
Deep vein thrombosis 20.14 16.96 60 15287 120859 79608182
Hypophagia 19.63 16.96 33 15314 45334 79683707
Gastritis 19.57 16.96 34 15313 47959 79681082
Actinomycotic skin infection 19.37 16.96 3 15344 6 79729035
Blood calcium increased 19.27 16.96 16 15331 10384 79718657
Gingivitis 19.09 16.96 15 15332 9006 79720035
Overdose 18.82 16.96 6 15341 184200 79544841
Feeling cold 18.26 16.96 25 15322 28704 79700337
Computerised tomogram abnormal 17.89 16.96 10 15337 3403 79725638
Monoclonal immunoglobulin present 17.80 16.96 7 15340 1078 79727963
Aspergilloma 17.55 16.96 6 15341 622 79728419
Therapeutic product effect decreased 17.35 16.96 5 15342 163858 79565183
Joint swelling 17.31 16.96 18 15329 288628 79440413
Post procedural diarrhoea 17.14 16.96 6 15341 668 79728373

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M05BA03 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
FDA CS M0006519 Diphosphonates
FDA EPC N0000175579 Bisphosphonate
MeSH PA D050071 Bone Density Conservation Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Osteolytic Lesions of Multiple Myeloma indication
Osteolytic Bone Metastases of Breast Cancer indication
Drug-induced osteoporosis off-label use 14651005
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Bone Metastases off-label use
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Periodontitis contraindication 41565005 DOID:824
Hypokalemia contraindication 43339004
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Pregnancy, function contraindication 289908002
Aseptic necrosis of bone of jaw contraindication 441809006
Thyroid Surgery contraindication
Invasive Dental Procedure contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.71 acidic
pKa2 4.78 acidic
pKa3 5.76 acidic
pKa4 9.83 acidic
pKa5 13.04 acidic
pKa6 11.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 7.25 CHEMBL CHEMBL
Farnesyl pyrophosphate synthase Enzyme Ki 6.72 CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Enzyme Ki 4.30 CHEMBL

External reference:

IDSource
D00941 KEGG_DRUG
109552-15-0 SECONDARY_CAS_RN
4020311 VANDF
4020543 VANDF
C3714572 UMLSCUI
CHEBI:7903 CHEBI
210 PDB_CHEM_ID
CHEMBL834 ChEMBL_ID
DB00282 DRUGBANK_ID
CHEMBL676 ChEMBL_ID
CHEMBL3989401 ChEMBL_ID
4674 PUBCHEM_CID
7259 IUPHAR_LIGAND_ID
6305 INN_ID
OYY3447OMC UNII
105443 RXNORM
42496 MMSL
5226 MMSL
d00601 MMSL
003616 NDDF
005066 NDDF
396032007 SNOMEDCT_US
420442001 SNOMEDCT_US
772820008 SNOMEDCT_US
96288007 SNOMEDCT_US
D000077268 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-601 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 mg INTRAVENOUS ANDA 24 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-602 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 6 mg INTRAVENOUS ANDA 24 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-603 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 9 mg INTRAVENOUS ANDA 24 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-324 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-325 INJECTION, SOLUTION 6 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-326 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-430 INJECTION 3 mg INTRAVENOUS ANDA 20 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-446 INJECTION 9 mg INTRAVENOUS ANDA 20 sections